These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38926480)

  • 21. Recreational use of psychedelics is associated with elevated personality trait openness: Exploration of associations with brain serotonin markers.
    Erritzoe D; Smith J; Fisher PM; Carhart-Harris R; Frokjaer VG; Knudsen GM
    J Psychopharmacol; 2019 Sep; 33(9):1068-1075. PubMed ID: 30816797
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Compassionate use of psychedelics.
    Greif A; Šurkala M
    Med Health Care Philos; 2020 Sep; 23(3):485-496. PubMed ID: 32468195
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discrete memory impairments in largely pure chronic users of MDMA.
    Wunderli MD; Vonmoos M; Fürst M; Schädelin K; Kraemer T; Baumgartner MR; Seifritz E; Quednow BB
    Eur Neuropsychopharmacol; 2017 Oct; 27(10):987-999. PubMed ID: 28866005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A prospective study of learning, memory, and executive function in new MDMA users.
    Wagner D; Becker B; Koester P; Gouzoulis-Mayfrank E; Daumann J
    Addiction; 2013 Jan; 108(1):136-45. PubMed ID: 22831704
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The influence of genetic and environmental factors among MDMA users in cognitive performance.
    Cuyàs E; Verdejo-García A; Fagundo AB; Khymenets O; Rodríguez J; Cuenca A; de Sola Llopis S; Langohr K; Peña-Casanova J; Torrens M; Martín-Santos R; Farré M; de la Torre R
    PLoS One; 2011; 6(11):e27206. PubMed ID: 22110616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Syllogistic reasoning performance in MDMA (Ecstasy) users.
    Montgomery C; Fisk JE; Newcombe R; Wareing M; Murphy PN
    Exp Clin Psychopharmacol; 2005 May; 13(2):137-45. PubMed ID: 15943546
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The costs and benefits of psychedelics on cognition and mood.
    Sayalı C; Barrett FS
    Neuron; 2023 Mar; 111(5):614-630. PubMed ID: 36681076
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Psychedelics and quasi-psychedelics in the light of contemporary research: medical cannabis, MDMA, salvinorin A, ibogaine and ayahuasca].
    Szabó A; Kazai A; Frecska E; Brys Z
    Neuropsychopharmacol Hung; 2015 Sep; 17(3):120-8. PubMed ID: 26485742
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Systematic Review of the Neurocognitive Effects of Psychedelics in Healthy Populations: Implications for Depressive Disorders and Post-Traumatic Stress Disorder.
    Velit-Salazar MR; Shiroma PR; Cherian E
    Brain Sci; 2024 Mar; 14(3):. PubMed ID: 38539636
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [3,4-methylenedioxymethamphetamine ('ecstasy'): its long-term emotional and cognitive effects, and serotonin depletion].
    Molero-Chamizo A
    Rev Neurol; 2005 Jul 16-31; 41(2):108-14. PubMed ID: 16028190
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The harmful health effects of recreational ecstasy: a systematic review of observational evidence.
    Rogers G; Elston J; Garside R; Roome C; Taylor R; Younger P; Zawada A; Somerville M
    Health Technol Assess; 2009 Jan; 13(6):iii-iv, ix-xii, 1-315. PubMed ID: 19195429
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aggressive behaviours associated with MDMA and psychedelics: a narrative review.
    Sayrafizadeh N; Ledwos N; Husain MI; Castle DJ
    Acta Neuropsychiatr; 2024 Feb; ():1-13. PubMed ID: 38329106
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long term psychiatric and cognitive effects of MDMA use.
    McGuire P
    Toxicol Lett; 2000 Mar; 112-113():153-6. PubMed ID: 10720725
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acute dose of MDMA (75 mg) impairs spatial memory for location but leaves contextual processing of visuospatial information unaffected.
    Kuypers KP; Ramaekers JG
    Psychopharmacology (Berl); 2007 Jan; 189(4):557-63. PubMed ID: 16508761
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The psychedelic afterglow phenomenon: a systematic review of subacute effects of classic serotonergic psychedelics.
    Evens R; Schmidt ME; Majić T; Schmidt TT
    Ther Adv Psychopharmacol; 2023; 13():20451253231172254. PubMed ID: 37284524
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term neuropsychiatric consequences of "ecstasy" (MDMA): a review.
    Montoya AG; Sorrentino R; Lukas SE; Price BH
    Harv Rev Psychiatry; 2002; 10(4):212-20. PubMed ID: 12119307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elevated impulsivity and impaired decision-making cognition in heavy users of MDMA ("Ecstasy").
    Quednow BB; Kühn KU; Hoppe C; Westheide J; Maier W; Daum I; Wagner M
    Psychopharmacology (Berl); 2007 Jan; 189(4):517-30. PubMed ID: 16425060
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential effects of MDMA and methylphenidate on social cognition.
    Schmid Y; Hysek CM; Simmler LD; Crockett MJ; Quednow BB; Liechti ME
    J Psychopharmacol; 2014 Sep; 28(9):847-56. PubMed ID: 25052243
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Safety and Efficacy of Psychedelic-Assisted Therapies for Older Adults: Knowns and Unknowns.
    Johnston CB; Mangini M; Grob C; Anderson B
    Am J Geriatr Psychiatry; 2023 Jan; 31(1):44-53. PubMed ID: 36184377
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes.
    Jones GM; Nock MK
    J Psychopharmacol; 2022 Jan; 36(1):57-65. PubMed ID: 34983261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.